CN1074911A - 将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法 - Google Patents

将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法 Download PDF

Info

Publication number: CN1074911A
Authority: CN; China
Prior art keywords: compound; alkyl; cell; group; general formula
Prior art date: 1991-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN92115176A

Other languages

English (en)

Chinese (zh)

Inventor

C·A·科皮亚

P·K·霍兰

B·D·格雷

D·E·特劳纳

K·A·米尔黑德

K·A·雪夫

C·-E·林

Z·余

S·Z·莱弗

K·E·拜杜

B·D·扬森

S·E·施列扎克

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zynaxis Technologies Inc

Original Assignee

Zynaxis Technologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-27

Filing date

1992-11-26

Publication date

1993-08-04

1992-05-15 Priority claimed from US07/884,432 external-priority patent/US5667764A/en

1992-11-26 Application filed by Zynaxis Technologies Inc filed Critical Zynaxis Technologies Inc

1993-08-04 Publication of CN1074911A publication Critical patent/CN1074911A/zh

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical group 0.000 title claims abstract description 510
238000000034 method Methods 0.000 title claims abstract description 114
230000031018 biological processes and functions Effects 0.000 title claims abstract description 53
239000000463 material Substances 0.000 title claims description 64
239000000203 mixture Chemical group 0.000 title claims description 53
230000001815 facial effect Effects 0.000 title description 7
238000011282 treatment Methods 0.000 claims abstract description 67
239000013543 active substance Substances 0.000 claims abstract description 32
239000002245 particle Substances 0.000 claims abstract description 29
238000005859 coupling reaction Methods 0.000 claims abstract description 24
230000008878 coupling Effects 0.000 claims abstract description 23
238000010168 coupling process Methods 0.000 claims abstract description 23
208000037803 restenosis Diseases 0.000 claims abstract description 20
210000004881 tumor cell Anatomy 0.000 claims abstract description 12
238000002399 angioplasty Methods 0.000 claims abstract description 11
201000003068 rheumatic fever Diseases 0.000 claims abstract description 10
230000004663 cell proliferation Effects 0.000 claims abstract 5
210000004027 cell Anatomy 0.000 claims description 242
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical group C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 99
-1 acylhydrazone Chemical class 0.000 claims description 89
QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 claims description 82
125000000217 alkyl group Chemical group 0.000 claims description 70
238000002347 injection Methods 0.000 claims description 61
239000007924 injection Substances 0.000 claims description 61
239000003795 chemical substances by application Substances 0.000 claims description 57
150000002430 hydrocarbons Chemical group 0.000 claims description 56
230000000694 effects Effects 0.000 claims description 55
229960001338 colchicine Drugs 0.000 claims description 52
229910052799 carbon Inorganic materials 0.000 claims description 49
230000001028 anti-proliverative effect Effects 0.000 claims description 42
239000003814 drug Substances 0.000 claims description 36
229920000669 heparin Polymers 0.000 claims description 35
229960002897 heparin Drugs 0.000 claims description 34
210000003743 erythrocyte Anatomy 0.000 claims description 33
210000004369 blood Anatomy 0.000 claims description 31
239000008280 blood Substances 0.000 claims description 31
239000000298 carbocyanine Substances 0.000 claims description 31
QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 claims description 30
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 29
238000001727 in vivo Methods 0.000 claims description 29
206010020718 hyperplasia Diseases 0.000 claims description 28
239000000126 substance Substances 0.000 claims description 28
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
230000021615 conjugation Effects 0.000 claims description 25
239000003352 sequestering agent Substances 0.000 claims description 25
206010028980 Neoplasm Diseases 0.000 claims description 24
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 24
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 24
230000002285 radioactive effect Effects 0.000 claims description 24
125000004432 carbon atom Chemical group C* 0.000 claims description 22
239000003153 chemical reaction reagent Substances 0.000 claims description 22
229910052736 halogen Inorganic materials 0.000 claims description 22
230000005855 radiation Effects 0.000 claims description 22
125000000524 functional group Chemical group 0.000 claims description 21
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 19
239000007788 liquid Substances 0.000 claims description 19
229910052751 metal Inorganic materials 0.000 claims description 19
239000002184 metal Substances 0.000 claims description 19
150000002148 esters Chemical class 0.000 claims description 18
230000006870 function Effects 0.000 claims description 18
150000002500 ions Chemical class 0.000 claims description 18
230000014759 maintenance of location Effects 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 17
210000004204 blood vessel Anatomy 0.000 claims description 16
238000002512 chemotherapy Methods 0.000 claims description 15
238000001959 radiotherapy Methods 0.000 claims description 15
239000011669 selenium Substances 0.000 claims description 15
229910052717 sulfur Inorganic materials 0.000 claims description 15
239000010949 copper Substances 0.000 claims description 14
150000002367 halogens Chemical class 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 13
229910052702 rhenium Inorganic materials 0.000 claims description 13
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 13
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 13
239000011735 vitamin B7 Substances 0.000 claims description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 12
125000001931 aliphatic group Chemical group 0.000 claims description 12
229910052738 indium Inorganic materials 0.000 claims description 12
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 12
229910052763 palladium Inorganic materials 0.000 claims description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
210000001772 blood platelet Anatomy 0.000 claims description 11
150000001721 carbon Chemical group 0.000 claims description 11
229910052802 copper Inorganic materials 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
201000004681 Psoriasis Diseases 0.000 claims description 10
125000004429 atom Chemical group 0.000 claims description 10
150000007857 hydrazones Chemical class 0.000 claims description 10
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
125000002877 alkyl aryl group Chemical group 0.000 claims description 9
150000001412 amines Chemical class 0.000 claims description 9
125000003710 aryl alkyl group Chemical group 0.000 claims description 9
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
229930003756 Vitamin B7 Natural products 0.000 claims description 8
150000008065 acid anhydrides Chemical class 0.000 claims description 8
125000000304 alkynyl group Chemical group 0.000 claims description 8
230000002785 anti-thrombosis Effects 0.000 claims description 8
235000020958 biotin Nutrition 0.000 claims description 8
239000011616 biotin Substances 0.000 claims description 8
229960002685 biotin Drugs 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
239000000975 dye Substances 0.000 claims description 8
230000003993 interaction Effects 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
230000000699 topical effect Effects 0.000 claims description 8
235000011912 vitamin B7 Nutrition 0.000 claims description 8
150000001241 acetals Chemical class 0.000 claims description 7
239000003146 anticoagulant agent Substances 0.000 claims description 7
229940127219 anticoagulant drug Drugs 0.000 claims description 7
229960004676 antithrombotic agent Drugs 0.000 claims description 7
150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 7
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 7
210000001519 tissue Anatomy 0.000 claims description 7
102000004895 Lipoproteins Human genes 0.000 claims description 6
108090001030 Lipoproteins Proteins 0.000 claims description 6
229910003849 O-Si Inorganic materials 0.000 claims description 6
229910003872 O—Si Inorganic materials 0.000 claims description 6
239000005864 Sulphur Substances 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
239000004202 carbamide Substances 0.000 claims description 6
239000003446 ligand Substances 0.000 claims description 6
125000005647 linker group Chemical group 0.000 claims description 6
150000002905 orthoesters Chemical class 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
229910052711 selenium Inorganic materials 0.000 claims description 6
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
229910052691 Erbium Inorganic materials 0.000 claims description 5
229910052689 Holmium Inorganic materials 0.000 claims description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 5
150000001409 amidines Chemical class 0.000 claims description 5
239000000427 antigen Substances 0.000 claims description 5
102000036639 antigens Human genes 0.000 claims description 5
108091007433 antigens Proteins 0.000 claims description 5
150000001615 biotins Chemical class 0.000 claims description 5
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 5
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 5
230000002163 immunogen Effects 0.000 claims description 5
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 5
229940124530 sulfonamide Drugs 0.000 claims description 5
150000003568 thioethers Chemical class 0.000 claims description 5
229910052727 yttrium Inorganic materials 0.000 claims description 5
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 4
TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims description 4
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 4
108090001008 Avidin Proteins 0.000 claims description 4
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
229910052765 Lutetium Inorganic materials 0.000 claims description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
229910052772 Samarium Inorganic materials 0.000 claims description 4
102000004243 Tubulin Human genes 0.000 claims description 4
108090000704 Tubulin Proteins 0.000 claims description 4
229910052769 Ytterbium Inorganic materials 0.000 claims description 4
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 4
125000002723 alicyclic group Chemical group 0.000 claims description 4
230000000973 chemotherapeutic effect Effects 0.000 claims description 4
229910052737 gold Inorganic materials 0.000 claims description 4
239000010931 gold Substances 0.000 claims description 4
229940006607 hirudin Drugs 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
150000002466 imines Chemical class 0.000 claims description 4
239000012948 isocyanate Substances 0.000 claims description 4
150000002513 isocyanates Chemical class 0.000 claims description 4
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 claims description 4
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
229910052703 rhodium Inorganic materials 0.000 claims description 4
239000010948 rhodium Substances 0.000 claims description 4
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
229910052713 technetium Inorganic materials 0.000 claims description 4
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims description 4
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 4
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 claims description 3
229930012538 Paclitaxel Natural products 0.000 claims description 3
230000006287 biotinylation Effects 0.000 claims description 3
238000007413 biotinylation Methods 0.000 claims description 3
239000000644 isotonic solution Substances 0.000 claims description 3
238000006386 neutralization reaction Methods 0.000 claims description 3
235000006408 oxalic acid Nutrition 0.000 claims description 3
229960001592 paclitaxel Drugs 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
230000035790 physiological processes and functions Effects 0.000 claims description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
239000011593 sulfur Substances 0.000 claims description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims description 2
150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
150000002463 imidates Chemical class 0.000 claims description 2
150000002540 isothiocyanates Chemical class 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
230000004962 physiological condition Effects 0.000 claims description 2
210000001258 synovial membrane Anatomy 0.000 claims description 2
150000003573 thiols Chemical group 0.000 claims description 2
239000003053 toxin Substances 0.000 claims description 2
231100000765 toxin Toxicity 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims 6
125000000623 heterocyclic group Chemical group 0.000 claims 3
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 2
229940095064 tartrate Drugs 0.000 claims 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
IHDBZCJYSHDCKF-UHFFFAOYSA-N 4,6-dichlorotriazine Chemical compound ClC1=CC(Cl)=NN=N1 IHDBZCJYSHDCKF-UHFFFAOYSA-N 0.000 claims 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
150000002118 epoxides Chemical class 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
229910052733 gallium Inorganic materials 0.000 claims 1
ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
230000009897 systematic effect Effects 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 54
201000010099 disease Diseases 0.000 abstract description 32
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 32
230000003750 conditioning effect Effects 0.000 abstract description 2
230000007170 pathology Effects 0.000 abstract description 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
239000000243 solution Substances 0.000 description 70
230000001225 therapeutic effect Effects 0.000 description 70
238000006243 chemical reaction Methods 0.000 description 55
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
239000004215 Carbon black (E152) Substances 0.000 description 31
229930195733 hydrocarbon Natural products 0.000 description 30
239000000523 sample Substances 0.000 description 30
239000000047 product Substances 0.000 description 29
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 28
102400000096 Substance P Human genes 0.000 description 27
101800003906 Substance P Proteins 0.000 description 27
235000018102 proteins Nutrition 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 27
238000012360 testing method Methods 0.000 description 27
238000003756 stirring Methods 0.000 description 26
229960004756 ethanol Drugs 0.000 description 25
241000283973 Oryctolagus cuniculus Species 0.000 description 23
108090000765 processed proteins & peptides Proteins 0.000 description 23
230000004044 response Effects 0.000 description 23
239000002585 base Substances 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
239000002904 solvent Substances 0.000 description 21
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 20
239000011541 reaction mixture Substances 0.000 description 20
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
239000000543 intermediate Substances 0.000 description 17
239000002609 medium Substances 0.000 description 17
239000011734 sodium Substances 0.000 description 17
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000010586 diagram Methods 0.000 description 16
238000005406 washing Methods 0.000 description 16
150000002632 lipids Chemical class 0.000 description 15
210000000056 organ Anatomy 0.000 description 15
230000000717 retained effect Effects 0.000 description 15
239000000741 silica gel Substances 0.000 description 15
229910002027 silica gel Inorganic materials 0.000 description 15
230000008859 change Effects 0.000 description 14
230000000875 corresponding effect Effects 0.000 description 14
238000005259 measurement Methods 0.000 description 14
239000012528 membrane Substances 0.000 description 14
210000004379 membrane Anatomy 0.000 description 14
238000002616 plasmapheresis Methods 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 13
229950002314 closilate Drugs 0.000 description 13
229940125961 compound 24 Drugs 0.000 description 13
239000012043 crude product Substances 0.000 description 13
238000001514 detection method Methods 0.000 description 13
239000012895 dilution Substances 0.000 description 13
238000010790 dilution Methods 0.000 description 13
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
238000000605 extraction Methods 0.000 description 13
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 13
125000006850 spacer group Chemical group 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
230000008901 benefit Effects 0.000 description 12
230000004087 circulation Effects 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
238000003818 flash chromatography Methods 0.000 description 12
210000003127 knee Anatomy 0.000 description 12
239000006228 supernatant Substances 0.000 description 12
239000010410 layer Substances 0.000 description 11
230000008569 process Effects 0.000 description 11
238000011160 research Methods 0.000 description 11
239000007787 solid Substances 0.000 description 11
238000012546 transfer Methods 0.000 description 11
210000002700 urine Anatomy 0.000 description 11
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 10
230000009471 action Effects 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
239000012141 concentrate Substances 0.000 description 10
239000011521 glass Substances 0.000 description 10
230000012010 growth Effects 0.000 description 10
238000003384 imaging method Methods 0.000 description 10
230000000813 microbial effect Effects 0.000 description 10
230000001575 pathological effect Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000000284 extract Substances 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
XEPNFUAOCCUBLC-UHFFFAOYSA-N 2,3-dihydro-1H-indole hydroiodide Chemical compound [I-].C1=CC=C2[NH2+]CCC2=C1 XEPNFUAOCCUBLC-UHFFFAOYSA-N 0.000 description 8
206010033128 Ovarian cancer Diseases 0.000 description 8
208000007536 Thrombosis Diseases 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
229910052786 argon Inorganic materials 0.000 description 8
230000027455 binding Effects 0.000 description 8
230000002939 deleterious effect Effects 0.000 description 8
238000009826 distribution Methods 0.000 description 8
239000007789 gas Substances 0.000 description 8
230000006872 improvement Effects 0.000 description 8
HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
230000009466 transformation Effects 0.000 description 8
238000010521 absorption reaction Methods 0.000 description 7
125000003368 amide group Chemical group 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
210000002808 connective tissue Anatomy 0.000 description 7
238000001035 drying Methods 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 7
150000002475 indoles Chemical class 0.000 description 7
230000010412 perfusion Effects 0.000 description 7
239000002243 precursor Substances 0.000 description 7
239000000376 reactant Substances 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
229920002554 vinyl polymer Polymers 0.000 description 7
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
102000007330 LDL Lipoproteins Human genes 0.000 description 6
108010007622 LDL Lipoproteins Proteins 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
210000001367 artery Anatomy 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
238000002161 passivation Methods 0.000 description 6
229920000573 polyethylene Polymers 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
210000000329 smooth muscle myocyte Anatomy 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 5
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 5
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 5
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 5
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
229960002587 amitraz Drugs 0.000 description 5
208000007502 anemia Diseases 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
229940126086 compound 21 Drugs 0.000 description 5
229940125833 compound 23 Drugs 0.000 description 5
238000012937 correction Methods 0.000 description 5
230000001351 cycling effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
210000001105 femoral artery Anatomy 0.000 description 5
238000007710 freezing Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
210000003141 lower extremity Anatomy 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000003068 molecular probe Substances 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000012266 salt solution Substances 0.000 description 5
230000002792 vascular Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
239000003643 water by type Substances 0.000 description 5
HBGVWZINWMBZJS-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-indole Chemical class C1=C(C)C(C)=C2C(C)=C(C)NC2=C1 HBGVWZINWMBZJS-UHFFFAOYSA-N 0.000 description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
229960001413 acetanilide Drugs 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000000536 complexating effect Effects 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 4
210000003617 erythrocyte membrane Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000011630 iodine Substances 0.000 description 4
150000002634 lipophilic molecules Chemical class 0.000 description 4
239000002502 liposome Substances 0.000 description 4
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000004417 polycarbonate Substances 0.000 description 4
229920000515 polycarbonate Polymers 0.000 description 4
239000004800 polyvinyl chloride Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000002390 rotary evaporation Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000012047 saturated solution Substances 0.000 description 4
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
IQMLCMKMSBMMGR-UHFFFAOYSA-N (4-iodophenyl)hydrazine Chemical compound NNC1=CC=C(I)C=C1 IQMLCMKMSBMMGR-UHFFFAOYSA-N 0.000 description 3
ADHFMENDOUEJRK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methyl]-n-hydroxypyrido[3,4-b]indole-3-carboxamide Chemical compound C1=NC(C(=O)NO)=CC(C2=CC=CC=C22)=C1N2CC1=CC=C(F)C=C1 ADHFMENDOUEJRK-UHFFFAOYSA-N 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
229920002683 Glycosaminoglycan Polymers 0.000 description 3
102000018997 Growth Hormone Human genes 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
241001482237 Pica Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229940122803 Vinca alkaloid Drugs 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
230000003915 cell function Effects 0.000 description 3
230000012292 cell migration Effects 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125797 compound 12 Drugs 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
229960000935 dehydrated alcohol Drugs 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000004821 distillation Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
238000010828 elution Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
125000001841 imino group Chemical group [H]N=* 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000000155 isotopic effect Effects 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
239000000693 micelle Substances 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
210000003200 peritoneal cavity Anatomy 0.000 description 3
238000001050 pharmacotherapy Methods 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
210000001147 pulmonary artery Anatomy 0.000 description 3
239000012217 radiopharmaceutical Substances 0.000 description 3
229940121896 radiopharmaceutical Drugs 0.000 description 3
230000002799 radiopharmaceutical effect Effects 0.000 description 3
239000002994 raw material Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
238000005070 sampling Methods 0.000 description 3
229920002379 silicone rubber Polymers 0.000 description 3
CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 3
229940071536 silver acetate Drugs 0.000 description 3
210000001179 synovial fluid Anatomy 0.000 description 3
229930192474 thiophene Natural products 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 2
VMDDSJXYVPDVLK-UHFFFAOYSA-N 2,3,4-trimethyl-1h-indole Chemical compound C1=CC(C)=C2C(C)=C(C)NC2=C1 VMDDSJXYVPDVLK-UHFFFAOYSA-N 0.000 description 2
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
241000553739 Aconitum carmichaelii var. truppelianum Species 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
229910052688 Gadolinium Inorganic materials 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
229940040526 anhydrous sodium acetate Drugs 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
239000013522 chelant Substances 0.000 description 2
BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
150000004696 coordination complex Chemical class 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000005281 excited state Effects 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
238000007429 general method Methods 0.000 description 2
230000008570 general process Effects 0.000 description 2
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
239000002634 heparin fragment Substances 0.000 description 2
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
150000002460 imidazoles Chemical class 0.000 description 2
239000012535 impurity Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
230000002083 iodinating effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
108010021336 lanreotide Proteins 0.000 description 2
229960002437 lanreotide Drugs 0.000 description 2
238000002350 laparotomy Methods 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000005291 magnetic effect Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920002529 medical grade silicone Polymers 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
210000004688 microtubule Anatomy 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
239000005445 natural material Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
210000004417 patella Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
238000002428 photodynamic therapy Methods 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000012797 qualification Methods 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000003439 radiotherapeutic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000002689 soil Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
229960002722 terbinafine Drugs 0.000 description 2
BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
125000002769 thiazolinyl group Chemical group 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229910052723 transition metal Inorganic materials 0.000 description 2
150000003624 transition metals Chemical class 0.000 description 2
229960000363 trapidil Drugs 0.000 description 2
PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 2
UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
238000007738 vacuum evaporation Methods 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
230000003245 working effect Effects 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
ZYECOAILUNWEAL-NUDFZHEQSA-N (4z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-n-(3-nitrophenyl)-3-oxonaphthalene-2-carboxamide Chemical compound COC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1N\N=C(C1=CC=CC=C1C=1)/C(=O)C=1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 ZYECOAILUNWEAL-NUDFZHEQSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
DQSHFKPKFISSNM-UHFFFAOYSA-N 2-methylbenzoxazole Chemical class C1=CC=C2OC(C)=NC2=C1 DQSHFKPKFISSNM-UHFFFAOYSA-N 0.000 description 1
DKJCREZWABCNBH-UHFFFAOYSA-N 2-n-(hydroxymethyl)benzene-1,2-dicarboxamide Chemical compound NC(=O)C1=CC=CC=C1C(=O)NCO DKJCREZWABCNBH-UHFFFAOYSA-N 0.000 description 1
KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
SMXSJALRXPANJM-UHFFFAOYSA-N 5-oxooxolane-2-sulfonic acid Chemical compound OS(=O)(=O)C1CCC(=O)O1 SMXSJALRXPANJM-UHFFFAOYSA-N 0.000 description 1
YVXGKAZJAUWMPM-UHFFFAOYSA-N 6-iodo-2-methyl-1,3-benzothiazole Chemical compound C1=C(I)C=C2SC(C)=NC2=C1 YVXGKAZJAUWMPM-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
102000008076 Angiogenic Proteins Human genes 0.000 description 1
108010074415 Angiogenic Proteins Proteins 0.000 description 1
101001044245 Arabidopsis thaliana Insulin-degrading enzyme-like 1, peroxisomal Proteins 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
244000186140 Asperula odorata Species 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
241000771208 Buchanania arborescens Species 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
229920004934 Dacron® Polymers 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
235000008526 Galium odoratum Nutrition 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100136062 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PE10 gene Proteins 0.000 description 1
239000005041 Mylar™ Substances 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 1
241000906034 Orthops Species 0.000 description 1
101100511042 Oryza sativa subsp. japonica LFL1 gene Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
241000011102 Thera Species 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108010021119 Trichosanthin Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000000999 acridine dye Substances 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
238000000516 activation analysis Methods 0.000 description 1
239000012190 activator Substances 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940125644 antibody drug Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
208000037873 arthrodesis Diseases 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000001743 benzylic group Chemical group 0.000 description 1
102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
229910052798 chalcogen Inorganic materials 0.000 description 1
150000001787 chalcogens Chemical class 0.000 description 1
208000003796 chancre Diseases 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000013016 damping Methods 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
229910000071 diazene Inorganic materials 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
150000002016 disaccharides Chemical group 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
125000005414 dithiopyridyl group Chemical group 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000004134 energy conservation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000005357 flat glass Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
231100000734 genotoxic potential Toxicity 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000012447 hatching Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003677 hemocyte Anatomy 0.000 description 1
229940000351 hemocyte Drugs 0.000 description 1
230000001951 hemoperfusion Effects 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000008676 import Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
229940006461 iodide ion Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical class NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
230000002969 morbid Effects 0.000 description 1
239000010813 municipal solid waste Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
RRHNGIRRWDWWQQ-UHFFFAOYSA-N n-iodoaniline Chemical compound INC1=CC=CC=C1 RRHNGIRRWDWWQQ-UHFFFAOYSA-N 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
210000004493 neutrocyte Anatomy 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
230000036407 pain Effects 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000003281 pleural cavity Anatomy 0.000 description 1
239000002574 poison Substances 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920003226 polyurethane urea Polymers 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000002601 radiography Methods 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
150000003282 rhenium compounds Chemical class 0.000 description 1
239000011435 rock Substances 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
238000002602 scintillography Methods 0.000 description 1
238000005201 scrubbing Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000009958 sewing Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
125000005629 sialic acid group Chemical group 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
229940001516 sodium nitrate Drugs 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940056501 technetium 99m Drugs 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
150000003538 tetroses Chemical class 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000004865 vascular response Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000001196 vasorelaxation Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1258—Pills, tablets, lozenges
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

CN92115176A 1991-11-27 1992-11-26 将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法 Pending CN1074911A (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US79893691A	1991-11-27	1991-11-27
US798,936		1991-11-27
US07/884,432 US5667764A (en)	1988-05-02	1992-05-15	Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US884,432		1992-05-15

Publications (1)

Publication Number	Publication Date
CN1074911A true CN1074911A (zh)	1993-08-04

Family

ID=27122052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN92115176A Pending CN1074911A (zh)	1991-11-27	1992-11-26	将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法

Country Status (10)

Country	Link
EP (1)	EP0643706A1 (fr)
JP (2)	JP3682974B2 (fr)
CN (1)	CN1074911A (fr)
AU (2)	AU3221993A (fr)
CA (1)	CA2124329C (fr)
IL (1)	IL103874A0 (fr)
MX (1)	MX9206844A (fr)
NZ (1)	NZ245271A (fr)
PH (1)	PH31676A (fr)
WO (1)	WO1993011120A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105745266A (zh) *	2013-11-26	2016-07-06	住友化学株式会社	橡胶组合物及硫化助剂

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100389223B1 (ko) *	1993-07-19	2003-10-08	안지오제네시스 테크놀로지스, 인코포레이티드	생체내통로관강을개방유지하기위한스텐트및이의제조방법
ATE255412T1 (de) *	1993-07-29	2003-12-15	Us Gov Health & Human Serv	Verfahren zur behandlung atherosklerose oder restenose mit hilfe eines mikrotubulusstabilisators
US5480901A (en) *	1994-10-07	1996-01-02	Zynaxis, Inc.	Method for reducing unwanted cellular adhesions
US6492332B1 (en)	1995-12-12	2002-12-10	Omeros Corporation	Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6004536A (en) *	1995-11-14	1999-12-21	Molecular Probes, Inc.	Lipophilic cyanine dyes with enchanced aqueous solubilty
WO1997024459A1 (fr) *	1995-12-29	1997-07-10	Phanos Technologoes, Inc.	Procede pour reduire les adherences cellulaires non desirees
US5871436A (en) *	1996-07-19	1999-02-16	Advanced Cardiovascular Systems, Inc.	Radiation therapy method and device
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en)	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
ES2388248T3 (es) *	1997-03-31	2012-10-11	Boston Scientific Scimed Limited	Forma de dosificación que comprende taxol en forma cristalina
US6241762B1 (en)	1998-03-30	2001-06-05	Conor Medsystems, Inc.	Expandable medical device with ductile hinges
US7208010B2 (en)	2000-10-16	2007-04-24	Conor Medsystems, Inc.	Expandable medical device for delivery of beneficial agent
US7208011B2 (en)	2001-08-20	2007-04-24	Conor Medsystems, Inc.	Implantable medical device with drug filled holes
US20040254635A1 (en)	1998-03-30	2004-12-16	Shanley John F.	Expandable medical device for delivery of beneficial agent
US7045305B1 (en) *	1998-04-08	2006-05-16	The Regents Of The University Of California	Methods and reagents for targeting organic compounds to selected cellular locations
EP1174157B1 (fr)	1998-04-27	2005-06-29	Surmodics Inc.	Revêtement destiné à libérer des agents bioactifs
US6120847A (en) *	1999-01-08	2000-09-19	Scimed Life Systems, Inc.	Surface treatment method for stent coating
US6333347B1 (en)	1999-01-29	2001-12-25	Angiotech Pharmaceuticals & Advanced Research Tech	Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en)	1999-02-03	2002-07-16	Scimed Life Systems, Inc.	Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en)	1999-05-03	2000-12-05	Scimed Life Systems, Inc.	Medical device coating methods and devices
NZ517188A (en) *	1999-08-23	2003-11-28	Angiogene Inc	Radioactively coated device and method of making same for preventing restenosis
CO5261573A1 (es)	1999-11-19	2003-03-31	Novartis Ag	Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
IT1319168B1 (it) *	2000-03-17	2003-09-26	Indena Spa	Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
DE60133053T2 (de)	2000-10-16	2009-02-26	Conor Medsystems, Inc., Menlo Park	Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
DE10115740A1 (de)	2001-03-26	2002-10-02	Ulrich Speck	Zubereitung für die Restenoseprophylaxe
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
US7056338B2 (en)	2003-03-28	2006-06-06	Conor Medsystems, Inc.	Therapeutic agent delivery device with controlled therapeutic agent release rates
DE10244847A1 (de)	2002-09-20	2004-04-01	Ulrich Prof. Dr. Speck	Medizinische Vorrichtung zur Arzneimittelabgabe
US7776529B2 (en)	2003-12-05	2010-08-17	Life Technologies Corporation	Methine-substituted cyanine dye compounds
WO2005099787A1 (fr)	2004-04-06	2005-10-27	Surmodics, Inc.	Compositions de revetement par agents bioactifs
USD516723S1 (en)	2004-07-06	2006-03-07	Conor Medsystems, Inc.	Stent wall structure
WO2006054904A2 (fr)	2004-11-22	2006-05-26	Ge Healthcare As	Agents de contraste
US9050393B2 (en)	2005-02-08	2015-06-09	Bruce N. Saffran	Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1885718B1 (fr)	2005-05-11	2017-03-15	Life Technologies Corporation	Composes chimiques fluorescents possedant une selectivite elevee pour l'adn double brin, et procedes d'utilisation
US8114429B2 (en)	2008-09-15	2012-02-14	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en)	2008-09-15	2012-09-04	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en)	2008-09-15	2015-12-01	The Spectranetics Corporation	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9956385B2 (en)	2012-06-28	2018-05-01	The Spectranetics Corporation	Post-processing of a medical device to control morphology and mechanical properties
US10525171B2 (en)	2014-01-24	2020-01-07	The Spectranetics Corporation	Coatings for medical devices
EP3101012A1 (fr)	2015-06-04	2016-12-07	Bayer Pharma Aktiengesellschaft	Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
JP7034160B2 (ja)	2016-11-28	2022-03-11	バイエル・ファルマ・アクティエンゲゼルシャフト	磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
CN113164628A (zh)	2018-11-23	2021-07-23	拜耳股份有限公司	造影介质制剂及其制备方法
JP7423888B2 (ja) *	2019-11-22	2024-01-30	株式会社同仁化学研究所	脂質二分子膜染色用色素及びそれを用いた脂質二分子膜の染色方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523965A (en) *	1976-03-19	1978-09-06	Ici Ltd	Pharmaceutical compositions containing steroids
DE3170134D1 (en) *	1980-09-02	1985-05-30	Fuji Photo Film Co Ltd	Method for immunochemical measurement
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US4751219A (en) *	1985-02-05	1988-06-14	Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek	Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US4762701A (en) *	1986-10-31	1988-08-09	Smithkline Beckman Corporation	In vivo cellular tracking
US4783401A (en) *	1986-10-31	1988-11-08	Smithkline Beckman Corporation	Viable cell labelling
US4906749A (en) *	1987-06-30	1990-03-06	Viomedics Inc.	Cyclic anhydride derivatives of chromophors
WO1989006654A1 (fr) *	1988-01-19	1989-07-27	Board Of Regents, The University Of Texas System	Glycosides, compositions liposomiques a base de ces composes et procedes d'utilisation
ATE145337T1 (de) *	1988-05-02	1996-12-15	Phanos Tech Inc	Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5149794A (en) *	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting

1992
- 1992-11-24 AU AU32219/93A patent/AU3221993A/en not_active Abandoned
- 1992-11-24 CA CA002124329A patent/CA2124329C/fr not_active Expired - Lifetime
- 1992-11-24 EP EP93900600A patent/EP0643706A1/fr not_active Withdrawn
- 1992-11-24 WO PCT/US1992/010076 patent/WO1993011120A1/fr not_active Application Discontinuation
- 1992-11-24 JP JP51019093A patent/JP3682974B2/ja not_active Expired - Lifetime
- 1992-11-25 NZ NZ245271A patent/NZ245271A/en unknown
- 1992-11-25 IL IL103874A patent/IL103874A0/xx unknown
- 1992-11-26 PH PH45327A patent/PH31676A/en unknown
- 1992-11-26 CN CN92115176A patent/CN1074911A/zh active Pending
- 1992-11-27 MX MX9206844A patent/MX9206844A/es unknown
1997
- 1997-04-30 AU AU19914/97A patent/AU1991497A/en not_active Abandoned
2002
- 2002-07-01 JP JP2002192417A patent/JP4095847B2/ja not_active Expired - Fee Related

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105745266A (zh) *	2013-11-26	2016-07-06	住友化学株式会社	橡胶组合物及硫化助剂
TWI637992B (zh) *	2013-11-26	2018-10-11	住友化學股份有限公司	Rubber composition and vulcanization aid
US10287419B2 (en)	2013-11-26	2019-05-14	Sumitomo Chemical Company, Limited	Rubber composition and vulcanization aid

Also Published As

Publication number	Publication date
WO1993011120A1 (fr)	1993-06-10
JP2003026657A (ja)	2003-01-29
NZ245271A (en)	1996-03-26
MX9206844A (es)	1993-07-01
JP3682974B2 (ja)	2005-08-17
JP4095847B2 (ja)	2008-06-04
JPH08502719A (ja)	1996-03-26
EP0643706A4 (fr)	1994-12-27
AU1991497A (en)	1997-07-10
EP0643706A1 (fr)	1995-03-22
PH31676A (en)	1999-01-18
CA2124329A1 (fr)	1993-06-10
AU3221993A (en)	1993-06-28
CA2124329C (fr)	2008-11-18
IL103874A0 (en)	1993-04-04

Publication	Publication Date	Title
CN1074911A (zh)	1993-08-04	将生物作用的物质结合至生物粒子面膜上的化合物，组合物和方法
CN1033030C (zh)	1996-10-16	大环双官能螯合剂及其配合物和抗体共轭物的制备方法
CN1087631C (zh)	2002-07-17	用于诊断和治疗的放射性标记肽
US5667764A (en)	1997-09-16	Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
Li et al.	2007	64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression
CN1230441C (zh)	2005-12-07	结合整联蛋白的肽衍生物
CN1622830A (zh)	2005-06-01	肽基化合物
CN1201005C (zh)	2005-05-11	特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
CN1093424C (zh)	2002-10-30	含单胺、联氨、硫羟基的金属螯合剂
CN108699108B (zh)	2022-04-08	放射性标记药物
CN1382062A (zh)	2002-11-27	通过多位点结合的寻靶多体造影剂
CN1747747A (zh)	2006-03-15	作为穿过血脑屏障的载体的抑酶肽及类似物
CN1295578A (zh)	2001-05-16	用于血管生成性疾病成像的药物
CN1606454A (zh)	2005-04-13	抗体靶向化合物
CN101537190A (zh)	2009-09-23	肽基化合物
JP2014507400A (ja)	2014-03-27	Ｎｏｔａによって錯体化されたアルミニウム−［１８ｆ］フッ化物で標識されたｈｅｒ２結合ペプチド
Achilefu et al.	2003	Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors
Machulkin et al.	2021	Synthesis, characterization, and preclinical evaluation of a small-molecule prostate-specific membrane antigen-targeted monomethyl auristatin E conjugate
US20220363623A1 (en)	2022-11-17	Imaging and therapeutic compositions
CN110709106A (zh)	2020-01-17	放射性标记的生物分子及其应用
CN1738652A (zh)	2006-02-22	用于药物化合物的改进的接头
Rajagopalan et al.	2002	Chemistry of bifunctional photoprobes. 6. Synthesis and characterization of high specific activity metalated photochemical probes: development of novel rhenium photoconjugates of human serum albumin and Fab fragments
CN115433261B (zh)	2023-01-13	一种rgd二聚体化合物及其制备方法和应用
Vaidyanathan et al.	2006	N ε-(3-[* I] iodobenzoyl)-Lys5-N α-maleimido-Gly1-GEEEK ([* I] IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies
Liu et al.	2007	Astatine-211 labeling of insulin: Synthesis and preliminary evaluation in vivo and in vitro

Legal Events

Date	Code	Title
1993-08-04	C06	Publication
1993-08-04	PB01	Publication
1995-03-29	C10	Entry into substantive examination
1995-03-29	SE01	Entry into force of request for substantive examination
1997-02-05	C01	Deemed withdrawal of patent application (patent law 1993)
1997-02-05	WD01	Invention patent application deemed withdrawn after publication